PCOS Is Now Called PMOS: What the Name Change Means and Why It Took So Long

The most common hormonal disorder affecting women of reproductive age affects approximately 1 in 8 women worldwide — an estimated 170 million people. The World Health Organization estimates that 70 percent of those affected have never been diagnosed. For decades, that diagnostic gap has been partly attributable to the name itself.

Polycystic ovary syndrome implies that the defining characteristic of the condition is the presence of cysts on the ovaries. Research has established that this is not accurate. There is no actual increase in abnormal ovarian cysts in people with the condition. Many women meet every other diagnostic criterion — irregular or absent periods, elevated male hormones, significant metabolic problems — without ever showing the ovarian appearance the name suggests. Clinicians who anchored on the ovarian finding were sending those women home without answers.

The new name — polyendocrine metabolic ovarian syndrome — describes the condition accurately. "Polyendocrine" acknowledges that multiple hormonal systems are involved. "Metabolic" recognizes the central role of insulin resistance and weight regulation. "Ovarian" preserves the reproductive dimension. The ovarian cysts that gave the condition its original name were a secondary observation — now correctly placed as one possible feature among several, not the definition of the disease.

What PMOS Is — and What It Isn't

PMOS is a complex, multisystem hormonal condition. Its core features include hormonal imbalance (elevated androgens — the group of hormones that includes testosterone — which cause acne, unwanted facial or body hair, and scalp thinning), irregular or absent menstrual cycles, difficulty with ovulation and fertility, and significant metabolic dysfunction centered on insulin resistance.

The metabolic component is the one that has the most significant long-term health consequences. Women with PMOS have substantially elevated lifetime risk of type 2 diabetes, high blood pressure, elevated cholesterol, and cardiovascular disease. They are also at increased risk for endometrial cancer. These risks persist and in some cases increase after menopause — meaning PMOS is not simply a reproductive-age condition that resolves when periods end.

PMOS also has a significant psychological dimension. Research consistently shows substantially higher rates of anxiety, depression, and disordered eating in women with the condition compared to the general population — a dimension that was consistently underrecognized under the PCOS framing, which tended to focus care on reproductive and cosmetic features.

The Women Who Were Never Diagnosed

The 70 percent undiagnosis rate is not a small rounding error. It represents tens of millions of women who have been managing a serious hormonal condition without the framework to understand it. For older women — those who are now in their 60s, 70s, or beyond — this means decades of unexplained symptoms that were often dismissed or attributed to other causes.

Irregular periods that were labeled as "just how you are." Weight that resisted every effort to control it, attributed to poor discipline rather than insulin resistance. Acne that persisted well past the teenage years. Anxiety that was treated as a separate psychological issue rather than recognized as a feature of a hormonal condition. Fertility challenges that were investigated in isolation.

Professor Helena Teede, who led the renaming initiative, noted that the name PCOS caused the diverse features of the condition to be "often unappreciated" — a polite way of saying that the label was leading clinicians away from the full picture. For women who were never diagnosed, understanding the condition now doesn't undo the past, but it can provide a framework that clarifies health history and informs ongoing care — including the elevated cardiovascular and metabolic risk monitoring that women with PMOS should be receiving.

What the Long-Term Health Picture Looks Like

For women who have PMOS — diagnosed or not — the long-term health implications extend well beyond the reproductive years. The insulin resistance that is central to the condition drives type 2 diabetes risk significantly: women with PMOS develop type 2 diabetes at roughly three to four times the rate of the general population and tend to develop it earlier. Screening for prediabetes and diabetes should be more frequent and begin earlier for women with PMOS than current general population guidelines recommend.

The cardiovascular risk is also meaningfully elevated. The combination of insulin resistance, elevated androgens, and the chronic inflammation associated with PMOS creates a risk profile that warrants more attentive monitoring of blood pressure, cholesterol, and other cardiovascular markers. The stroke risk associated with untreated hypertension and metabolic syndrome is a particular concern for women with undiagnosed or undermanaged PMOS who have carried these risk factors for decades.

The endometrial cancer risk comes from irregular ovulation. In women who ovulate infrequently, the uterine lining builds up without the regular shedding that monthly cycles provide, creating conditions under which cellular changes can occur over time. This risk can be managed, but it requires awareness and appropriate gynecological follow-up.

What to Bring to Your Doctor

If you are a woman who has experienced irregular periods throughout your life, persistent skin or hair changes consistent with elevated androgens, significant difficulty managing weight, a diagnosis of prediabetes or insulin resistance, or a history of fertility challenges — and you have never been evaluated for PMOS — it is worth raising the question with your doctor, regardless of your current age.

For women who are post-menopausal: the diagnosis at this stage is retrospective, but it has practical value for understanding your risk profile. A provider who knows you have PMOS will screen your metabolic and cardiovascular health with appropriate frequency and watch for the specific risks associated with the condition. Mention your symptom history, your menstrual history going back to your teens, and any relevant family history.

For family members of women who were diagnosed with PCOS: the condition carries a genetic component. Daughters and granddaughters of women with PMOS have an elevated risk of the condition. The new name and the updated diagnostic criteria — which no longer require polycystic ovaries — may make it easier for younger family members to receive an accurate diagnosis earlier than their mothers and grandmothers did.

The Transition Timeline

The name change does not happen overnight in clinical practice. The Endocrine Society and its 56 partner organizations have announced a three-year transition period, with full implementation — including updated clinical guidelines — expected by the 2028 International Guideline update. In the interim, clinicians may use PCOS and PMOS interchangeably, and insurance and billing systems will continue to use the existing PCOS diagnostic codes during the transition.

Patient advocate Lorna Berry of Verity, the UK's leading PCOS/PMOS patient charity, described the renaming as "about accountability and progress" for future generations of patients. For women who were never properly diagnosed, or who struggled for years to have their symptoms taken seriously, that accountability is not abstract.